Global Intra-Aortic Balloon Pump Market - 2022-2029

Global Intra-Aortic Balloon Pump Market - 2022-2029

Market Overview

The global intra-aortic balloon pump market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

An intra-aortic balloon pump (IABP) is a mechanical device that provides temporary support to the heart. It works by inflating a small balloon inside the aorta, which helps to increase blood flow to the heart and other organs. The IABP is typically used in patients with severe heart problems, such as heart failure or cardiogenic shock, and is inserted through a catheter passed through an artery, usually the femoral artery in the groin. The IABP is typically used temporarily until other treatments, such as surgery or medication, can improve the patient's condition.

Market Dynamics

The global intra-aortic balloon pump market growth is driven by increasing cases of coronary artery diseases like unstable angina and myocardial infarction, the surging prevalence of cardiovascular diseases, a growing obese populace, advancing lifestyle disorders, and the evolving global healthcare infrastructure.

An increasing number of cardiovascular diseases drives the market growth

The surging prevalence of cardiovascular diseases and technological advancements drive the market worldwide. As per the article published in StatPearls in 2022, coronary artery disease (CAD) is the most frequent form of heart disease. It is the result of atheromatous differences in the vessels providing the heart. CAD represents a scope of clinical disorders, from asymptomatic atherosclerosis and stable angina to acute coronary syndrome (unstable angina, NSTEMI, STEMI). In the U.S., it is still one of the leading causes of mortality. Initial evaluation of risk factors is the first step in preventing coronary artery diseases.

Chronic stable angina affects approximately 30000 to 40000 people per million people in western countries. Prevalence rises with age in both men and women. The prevalence rates for men and women 45 to 64 years old are 4 to 7% and 5 to 7%, respectively. In men and women 65 to 84 years old, the estimated prevalence is 14 to 15% and 10 to 12%, respectively.

Intra-aortic balloon pumping can increase coronary blood flow and decrease left ventricular load, thereby improving the balance of oxygen supply to the heart, reducing the area of ischemia and protecting cardiomyocytes from dying. This technique could provide critical temporary support for the functioning of the left ventricle and help to prevent ischemic heart failure, thereby reducing peri-operative mortality associated with coronary artery bypass grafting.

The side effects associated with intra-aortic balloon pumps will hamper the growth of the market

However, the use of an intra-aortic balloon pump (IABP) is generally considered safe, but there are some potential side effects and complications associated with its use. These can include Arterial or vascular complications. These may include bleeding, hematoma, or puncture of the artery where the catheter is inserted. Infection as with any invasive process, there is a risk of infection at the site of the catheter insertion. Blood clots can form on the balloon or the catheter, blocking blood flow. Arrhythmias The IABP can cause irregular heartbeats, which can be dangerous for some patients. Heart or lung injury in rare cases, the IABP can cause injury to the heart or lungs. Kidney injury IABP can cause a decrease in blood flow to the kidneys, leading to kidney injury. Limb ischemia IABP may cause a decrease in blood flow to the limb in which the catheter was inserted.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant effect on cardiac surgery worldwide. Many hospitals have had to reduce or suspend non-emergency surgeries, including cardiac surgeries, to conserve resources for COVID-19 patients. This has reduced the number of surgeries performed and the backlog of patients waiting for surgery. As per the article published in the Archives of Cardiovascular Diseases in 2021, Cardiac surgery systematically requires postoperative intensive care. As these specialized units were reserved for patients with COVID-19 necessitating respiratory support, elective open-heart surgeries were substantially delayed in almost all French centers.

Furthermore, some cardiac patients may be at a higher risk of severe illness from COVID-19 due to underlying heart conditions, which may make them more hesitant to seek treatment. The pandemic also decreased the number of patients admitted to hospitals for heart attacks, which is believed to be due to people being afraid to seek medical attention out of fear of getting COVID-19. This decreased hospital revenue, resulting in some downsizing of services, including cardiac services.

Overall, the COVID-19 pandemic has had a significant impact on cardiac surgery worldwide, leading to a decrease in the number of surgeries being performed and a backlog of patients waiting for surgery, as well as affecting the availability of medical staff and equipment and leading to a decrease in revenue for hospitals.

Segment Analysis

The intra - aortic balloon pump (IABP) catheters segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The intra - aortic balloon pump (IABP) catheters segment accounts for the highest market share. An intra-aortic balloon pump (IABP) is a device to help increase blood flow to the body's vital organs, such as the heart and brain, during a cardiac event such as a heart attack. The device consists of a catheter inserted into the patient's aorta and a small balloon inflated and deflated in sync with the patient's heartbeat. This action helps to increase the amount of blood that is pumped to the body's vital organs during the diastolic phase of the heart's pumping cycle. IABP is used as a temporary measure for cardiac disorders. This invasive procedure is used in critical care units and cardiac catheterization labs.

In addition, Meril Life Sciences offers Intra Aortic Balloon Catheter Kit, a device placed in the descending aorta. Balloon inflation in the aorta during diastole and deflation during systole increase blood supply to the heart muscle and decrease the work of the left ventricle.

Geographical Analysis

North America region holds the largest market share of the global Intra-Aortic Balloon Pump market

North America dominates the market for Intra-Aortic Balloon Pumps and is expected to show a similar trend over the forecast period. Technological advancements, the rising prevalence of heart disease, and product launches by market players in the North American region drive the market.

Each year, more than 900,000 Americans suffer a heart attack or pass away suddenly from cardiac causes. In addition, acute coronary syndromes account for over 400,000 annual fatalities. About two-thirds are men, and almost all have underlying coronary artery disease.

According to Heart Disease and Stroke Prevention, about 697,000 Americans yearly, or 1 in every five deaths, are caused by heart disease. The most prevalent form of heart disease, coronary heart disease (CHD), claims the lives of over 382,820 people yearly. Approximately 805,000 Americans experience a heart attack each year. Six hundred and five thousand of these result in a first-time heart attack, while previous heart attacks cause 200,000. Rising heart-related disorders in the North American region drive the market.

Competitive Landscape

The intra-aortic balloon pump market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Medtronic, Teleflex Incorporated, Abiomed Inc, Smiths Group plc, Getinge AB, ATMOS Medizin Technik GmbH & Co. KG, ARGON MEDICAL, Cook, MAQUET Holding B.V. & Co. KG, LivaNova PLC, and Cook, among others. The major players are adopting several growth strategies, such as Type launches, acquisitions, and collaborations, contributing to the growth of the intra-aortic balloon pump market globally.

Medtronic

Overview:

Medtronic is a medical device company founded in 1949 and headquartered in the United States. Groundbreaking healthcare technology solutions for the most complex and challenging conditions.

Product Portfolio:

Euphora Semicompliant Balloon Catheter: Euphora semi-compliant balloon dilatation catheter complements the patient's expertise and provides uncompromising performance when the patient needs it most.

The global intra-aortic balloon pump market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.